InvestorNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial
June 16, 2025
Lantern Pharma (NASDAQ: LTRN) announced a remarkable clinical outcome in its Phase 2 HARMONIC(TM) trial, with a 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) achieving a durable complete response following treatment with LP-300 in combination with standard chemotherapy. The patient, who had previously failed three lines of therapy including Keytruda(R), radiation, and Tagrisso(R), initially […]
Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’
June 11, 2025
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. The company has gained 11 FDA Designations for its portfolio of drug candidates including: Fast […]
InvestorNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Highlights LP-184 Preclinical Success in Pediatric Brain Cancer ATRT
May 30, 2025
Lantern Pharma (NASDAQ: LTRN) reported strong preclinical results for LP-184 in atypical teratoid rhabdoid tumors (“ATRT”), a rare and aggressive pediatric brain cancer. Presented by Dr. Eric Raabe of Johns Hopkins at the Society for Neuro-Oncology’s Pediatric Neuro-Oncology Conference, the data showed LP-184 significantly improved survival in two mouse models, with one model achieving a […]
InvestorNewsBreaks – Lantern Pharma Inc. (LTRN) Expands HARMONIC™ Trial to Asia with First Patient Dosed in Taiwan
December 18, 2024
Lantern Pharma (LTRN) has enrolled and dosed its first patient in Taiwan for the Phase 2 HARMONIC™ trial evaluating LP-300 in never-smokers with non-small cell lung cancer (“NSCLC”) who have relapsed after tyrosine kinase inhibitor (“TKI”) treatment. This expansion into Asia addresses the region’s higher prevalence of never-smoker NSCLC cases, with Taiwan being a key […]
InvestorNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) to Present at RHK Capital Disruptive Growth Conference
December 2, 2022
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR(R) artificial intelligence (“AI””) and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, will be participating in the upcoming RHK Capital Disruptive Growth Conference. Slated for Dec. 5, 2022, the conference will be held in New York […]
Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET
December 2, 2022
DALLAS, Dec. 02, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Lantern Pharma Inc (Nasdaq: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announces that Panna Sharma, CEO and President, will present at the […]
Sound Results for illimity Also in the Second Quarter of 2022
August 5, 2022
Net Profit of 15.8 Million Euro (+6% Y/Y), Bringing the Net Result for the First Half Year to 31.5 Million Euro (+15% vs 1H21)Earnings Driven by Growth in Revenue, Which Rose to 80.6 Million Euro in 2Q22 (+13% Y/Y), illimity’s Best Quarterly Figure, and to 159 Million Euro in 1H22 (+25% Y/Y)Net Customer Loans at […]
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies
November 15, 2021
Virtual: November 16 – 17, 2021 Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 presenting companies from a wide spectrum […]
Lantern Pharma Inc. (NASDAQ: LTRN) Featured in Virtual Coverage of Benzinga’s Global Small Cap Conference
December 9, 2020
Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. The company leverages advances in machine learning, genomics and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to its pipeline of cancer […]